Advances in Oncology, 2024
- 1st Edition, Volume 4-1 - April 1, 2024
- Latest edition
- Editor: Leonidas C. Platanias
- Language: English
Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information… Read more
Purchase options
Description
Description
Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information they need to improve patient outcomes. A distinguished editorial board, led by Dr. Leonidas C. Platanias, identifies key areas of major progress and controversy and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in oncology inform and enhance clinical practice by bringing concepts to a clinical level and exploring their everyday impact on patient care.
Key features
Key features
- Contains 26 articles on such topics as management of locoregional melanoma; surgery for recurrent ovarian cancer; advances in pediatric cancer with big data: the Pediatric Cancer Data Commons; advanced imaging in gliomas; approach to minimal residual disease for acute myeloid leukemia; treatment options for HER2-expressing gastroesophageal cancers; and more
- Provides in-depth, clinical reviews in oncology, providing actionable insights for clinical practice
- Presents the latest information in the field under the leadership of an experienced editorial team. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews
Readership
Readership
Oncology
Table of contents
Table of contents
1. Contemporary Management of Dermatofibrosarcoma Protuberans
2. Management of Locoregional Melanoma
3. Current Management of Intraductal Papillary Mucinous Neoplasms
4. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy
5. Optimal Front-Line Therapy for Non[1]Oncogene-Driven Non-Small Cell Lung Cancer
6. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance
7. Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application
8. Surgery for Recurrent Ovarian Cancer
9. Big Data in Pediatric Oncology: Hope, Hype, Reality
10. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas
11. Diagnostic and Theranostic Opportunities in Neuro-Oncology
12. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis
13. Management of Relapsed Refractory Large B[1]Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation
14. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching
15. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia
16. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer
17. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: 18. Patient Selection and Overview of Doublet and Triplet Therapy Data
19. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions
20. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers
21. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
22. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
23. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
2. Management of Locoregional Melanoma
3. Current Management of Intraductal Papillary Mucinous Neoplasms
4. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy
5. Optimal Front-Line Therapy for Non[1]Oncogene-Driven Non-Small Cell Lung Cancer
6. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance
7. Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application
8. Surgery for Recurrent Ovarian Cancer
9. Big Data in Pediatric Oncology: Hope, Hype, Reality
10. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas
11. Diagnostic and Theranostic Opportunities in Neuro-Oncology
12. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis
13. Management of Relapsed Refractory Large B[1]Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation
14. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching
15. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia
16. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer
17. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: 18. Patient Selection and Overview of Doublet and Triplet Therapy Data
19. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions
20. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers
21. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers
22. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma
23. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 4-1
- Published: April 10, 2024
- Language: English
About the editor
About the editor
LP
Leonidas C. Platanias
Director Leonidas C. Platanias works at the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Professor of Medicine (Hematology and Oncology) and Biochemistry and Molecular Genetics, USA.
Affiliations and expertise
Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Professor of Medicine (Hematology and Oncology) and Biochemistry and Molecular Genetics, USA